Global CD47 Inhibitor Drug Clinical Trials Insight 2028 Report Highlights:
- CD47 Inhibitor Drug Market Trends & Future Prospects
- Insight On More Than 50 CD47 Inhibitors Drugs In Clinical Trials
- Orphan, Fast Track, Breakthrough Therapy Designation Insight
- Insight On CD47 Inhibitors Drugs Biomarkers Sourced During Clinical Trials
- CD47 Inhibitors Drug Clinical Trials Insight By Company, Indication & Phase
- CD47 Inhibitors Drug Clinical Trials Insight As Mono & Combination Therapy
- Global CD47 Inhibitor Drug Market Dynamics
Download Report Sample: https://www.kuickresearch.com/report-cd47-inhibitor-drugs-clinical-trials
Researchers have always been intrigued and fascinated by the ways cancer cells are able to evade the immune system. An important transmembrane protein whose role has been established in this process is the CD47, also known as the integrin associated protein (IAP). The expression of CD47 on tumor surface sends a “don’t eat me” signal to macrophages which help tumors to hide from the immune cells. The protein is overexpressed on several cancers, which is why CD47 has been attracting researchers and drug developers for a long time now.
To block the signals going off from the CD47 protein, antibodies have been developed and several are in clinical trials for assessing their efficacy in cancer. Magrolimab developed by Gilead, is perhaps the most well-known and a promising candidate in the clinical pipeline. It was also the first anti-CD47 antibody to enter clinical trials. It has been granted the orphan drug designations from the FDA and EMA and also has a breakthrough designation from the FDA. Additionally, AO-176 (Arch Oncology), Evorpacept/ ALX148 (ALX Oncology) and PT886 (Phanes Therapeutics) are some of the more recent CD47 blockers to get the orphan drug designation from the FDA for various cancer indications. In addition to its orphan drug designation, Evorpacept also has a Fast Track Designation from the FDA. All these designations were based on the promising results shown by these candidates.
At present, no anti CD47 antibody has been granted approval; however, the above mentioned drugs have indicated a potential future for thee drugs. Targeted therapy with CD47- directed antibodies is a form of immunotherapy. Immunotherapies have been used for cancer management and treatment for a long time and the discovery of new targets is making the therapy even more favorable. Although immunotherapies show great effects in monotherapy, when used in combination with other treatment modalities, its effects are further enhanced. Therefore, pharmaceutical companies are now also assessing the combinations of these antibodies with other drugs and conventional therapies to have better therapeutic results arising from the mutual benefits of the two therapies.
As more researchers are involved in the development of these drugs, companies are investing highly in order to develop drugs with better targeting and therapeutic potential to have an edge over their competitors. With several talented and knowledgeable researchers working in the field, combined with the benefits provided by technologically advanced platforms, more innovations are taking place which have made the new generation antibodies better than the previous. One of the more recent developments to take place is the entry of bispecific antibodies in treating cancers overexpressing CD47. An anti- CD47/PD-L1 bispecific antibody has been developed against lymphoma. The blocking the CD47, it prevents the tumor from hiding from the macrophages and at the same time, blocking the PD-L1 removes the breaks from the immune system, both allowing a full scale attack on cancer cells, thus reducing the tumor burden, which can later be decreased further through chemotherapy. NI-1701 and LQ007 are other bispecific antibodies under development targeting the CD47 along with another protein.
The clinical pipeline of CD47 antibodies is comparatively less populated when compared to others proteins with targeted antibodies which shows there is room to explore further. China and the US are currently leading the pipeline with several drugs in development with the involvement of companies like Akeso, Sorrento Therapeutics, Pfizer and ALX Oncology among others. While most of the candidates are in early phases of clinical trials, some few have advanced to the phase II. With so many candidates in the same phase, the competition is already high among them to become the first drug to enter the market and to enjoy the benefits associated with early entry.
There is an unmet need for cancer treatment methods to help patients whose bodies develop resistance to their prescribed treatment procedure. The emergence CD47 provides additional hope to patients with cancers over expressing CD47. The pipeline has several candidates in early stages of clinical trials and the approval of the first anti-CD47 antibody has the potential to further expand the pipeline because of the entry of new candidates and the coverage of more indications.